Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 27;11(2):369.
doi: 10.3390/biomedicines11020369.

Statin Use Ameliorates Survival in Oral Squamous Cell Carcinoma-Data from a Population-Based Cohort Study Applying Propensity Score Matching

Affiliations

Statin Use Ameliorates Survival in Oral Squamous Cell Carcinoma-Data from a Population-Based Cohort Study Applying Propensity Score Matching

Steffen Spoerl et al. Biomedicines. .

Abstract

The anti-cancer properties of statins have attracted much attention recently, but little is known about the prognostic role of statins in oral squamous cell carcinoma (OSCC). In a retrospective approach, we analyzed a population-based cohort of 602 OSCC patients with primary curative tumor resection to negative margins and concomitant neck dissection between 2005-2017. Long-term medication with statins was correlated with overall survival (OAS) as well as recurrence-free survival (RFS) using uni- and multivariable Cox regression. Additionally, propensity score matching was applied to adjust for confounders. Statin use was present in 96 patients (15.9%) at a median age of 65.7 years. Statin treatment correlated with ameliorated survival in multivariable Cox regression in the complete cohort (OAS: HR 0.664; 95% CI 0.467-0.945, p = 0.023; RFS: HR 0.662; 95% CI 0.476-0.920, p = 0.014) as well as matched-pair cohort of OSCC patients (OAS: HR 0.691; 95% CI 0.479-0.997, p = 0.048; RFS: HR 0.694; 95% CI 0.493-0.976, p = 0.036) when compared to patients not taking statins at time of diagnosis. These findings were even more pronounced by sub-group analysis in the matched-pair cohort (age < 70 years). These data indicate that statin use might ameliorate the oncological outcome in primarily resected OSCC patients, but prospective clinical trials are highly recommended.

Keywords: CVD; HNSCC; OSCC; PSM; cardiovascular disease; hydroxymethylglutaryl CoA reductase inhibitor; oral squamous cell carcinoma; propensity score matching; statin; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Survival in a matched-pair cohort of OSCC patients with age at diagnosis <50 years (n = 359) comparing patients taking statins to those patients without statin treatment: (A): Kaplan–Meier analysis for OAS (p = 0.099); (B): Kaplan–Meier analysis for RFS (p = 0.074).
Figure 2
Figure 2
Survival in a matched-pair cohort of OSCC patients with age at diagnosis <70 years (n = 246) comparing patients taking statins at the time of diagnosis compared to those patients without statin treatment: (A): Kaplan–Meier analysis for OAS (p = 0.014); (B): Kaplan–Meier analysis for RFS (p = 0.032).

Similar articles

Cited by

References

    1. Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Cheng S., Delling F.N., et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143:e254–e743. doi: 10.1161/CIR.0000000000000950. - DOI - PubMed
    1. Dawber T.R., Meadors G.F., Moore F.E., Jr. Epidemiological approaches to heart disease: The Framingham Study. Am. J. Public Health Nations Health. 1951;41:279–281. doi: 10.2105/AJPH.41.3.279. - DOI - PMC - PubMed
    1. Mahmood S.S., Levy D., Vasan R.S., Wang T.J. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet. 2014;383:999–1008. doi: 10.1016/S0140-6736(13)61752-3. - DOI - PMC - PubMed
    1. D’Agostino R.B., Sr., Pencina M.J., Massaro J.M., Coady S. Cardiovascular Disease Risk Assessment: Insights from Framingham. Glob. Heart. 2013;8:11–23. doi: 10.1016/j.gheart.2013.01.001. - DOI - PMC - PubMed

LinkOut - more resources